This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
We haven't written up this one. MarketWatch Top has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.